Literature DB >> 10585431

Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2).

A W Ashton1, R Yokota, G John, S Zhao, S O Suadicani, D C Spray, J A Ware.   

Abstract

The eicosanoid thromboxane A(2) (TXA(2)) is released by activated platelets, monocytes, and the vessel wall and interacts with high affinity receptors expressed in several tissues including endothelium. Whether TXA(2) might alter endothelial migration and tube formation, two determinants of angiogenesis, is unknown. Thus, we investigated the effect of the TXA(2) mimetic [1S-(1alpha, 2beta(5Z),3alpha(1E,3R), 4alpha]-7-[3-(3-hydroxy-4-(4'-iodophenoxy)-1-butenyl)-7-o xab icyclo- [2.2.1]heptan-2-yl]-5'-heptenoic acid (IBOP) on human endothelial cell (HEC) migration and angiogenesis in vitro. IBOP stimulation inhibited HEC migration by 50% and in vitro capillary formation by 75%. These effects of IBOP were time- and concentration-dependent with an IC(50) of 25 nM. IBOP did not affect integrin expression or cytoskeletal morphology of HEC. Since gap junction-mediated intercellular communication increases in migrating HEC, we determined whether IBOP might inhibit coupling or connexin expression in HEC. IBOP reduced the passage of microinjected dyes between HEC by 50%, and the effects of IBOP on migration and tube formation were mimicked by the gap junction inhibitor 18beta-glycyrrhetinic acid (1 microM) with a similar time course and efficacy. IBOP (24 h) did not affect the expression or phosphorylation of connexin 43 in whole HEC lysates. Immunohistologic examination of HEC suggested that IBOP may impair functional coupling by altering the cellular distribution of gap junctions, leading to increased connexin 43 internalization. Thus, this finding that TXA(2) mimetics can prevent HEC migration and tube formation, possibly by impairing intercellular communication, suggests that antagonizing TXA(2) signaling might enhance vascularization of ischemic tissue.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10585431     DOI: 10.1074/jbc.274.50.35562

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Tbx6 is a determinant of cardiac and neural cell fate decisions in multipotent P19CL6 cells.

Authors:  Svetlana Gavrilov; Thomas G Nührenberg; Anthony W Ashton; Chang-Fu Peng; Jennifer C Moore; Klitos Konstantinidis; Christine L Mummery; Richard N Kitsis
Journal:  Differentiation       Date:  2012-06-19       Impact factor: 3.880

Review 2.  Roles of gap junctions and connexins in non-neoplastic pathological processes in which cell proliferation is involved.

Authors:  Maria Lúcia Zaidan Dagli; Francisco Javier Hernandez-Blazquez
Journal:  J Membr Biol       Date:  2007-07-25       Impact factor: 1.843

3.  Antiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX): in vitro and in vivo.

Authors:  Yue Huang; Xiao-Mei Chen; Bing-Xiang Zhao; Xi-Yu Ke; Bo-Jun Zhao; Xin Zhao; Ying Wang; Xuan Zhang; Qiang Zhang
Journal:  AAPS PharmSciTech       Date:  2010-05-05       Impact factor: 3.246

Review 4.  The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis.

Authors:  Prasanna Ekambaram; Wanyu Lambiv; Rosanna Cazzolli; Anthony W Ashton; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

5.  Characterization of endothelial thromboxane receptors in rabbit aorta.

Authors:  Sandra L Pfister
Journal:  Prostaglandins Other Lipid Mediat       Date:  2008-09-02       Impact factor: 3.072

6.  Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.

Authors:  Jacob H Rand; Xiao-Xuan Wu; Anthony S Quinn; Anthony W Ashton; Pojen P Chen; James J Hathcock; Harry A M Andree; Douglas J Taatjes
Journal:  Blood       Date:  2009-11-30       Impact factor: 22.113

7.  Liver kinase B1 is required for thromboxane receptor-dependent nuclear factor-κB activation and inflammatory responses.

Authors:  Jinlong He; Yanhong Zhou; Junjie Xing; Qilong Wang; Huaiping Zhu; Yi Zhu; Ming-Hui Zou
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-03-28       Impact factor: 8.311

8.  Thromboxane A2 receptor activates a Rho-associated kinase/LKB1/PTEN pathway to attenuate endothelium insulin signaling.

Authors:  Ping Song; Miao Zhang; Shuangxi Wang; Jian Xu; Hyoung Chul Choi; Ming-Hui Zou
Journal:  J Biol Chem       Date:  2009-04-29       Impact factor: 5.157

9.  Thromboxane receptor stimulation associated with loss of SKCa activity and reduced EDHF responses in the rat isolated mesenteric artery.

Authors:  G J Crane; C J Garland
Journal:  Br J Pharmacol       Date:  2004-03-29       Impact factor: 8.739

10.  Differential regulation of RhoA-mediated signaling by the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor: independent modulation of TPalpha signaling by prostacyclin and nitric oxide.

Authors:  Katarina Wikström; David J Kavanagh; Helen M Reid; B Therese Kinsella
Journal:  Cell Signal       Date:  2008-05-23       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.